Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02JDN
|
|||
| Former ID |
DIB008354
|
|||
| Drug Name |
IFN-alpha
|
|||
| Synonyms |
Hanferon; HL-143; IFN-alpha (sc injection, HCV infection); Belerofon (subcutaneous, HCV infection), Nautilus/HanAll; IFN-alpha (sc injection, HCV infection), HanAll; IFN-alpha (subcutaneous, HCV infection), Nautilus/HanAll; Interferon-alpha (subcutaneous, HCV infection), Nautilus/HanAll
Click to Show/Hide
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 2 | [1] | |
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 2 | [2] | ||
| Company |
Hanall biopharma
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017807) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.